Premium
Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
Author(s) -
Osorio S.,
Noblejas A. García,
Durán A.,
Steegmann J.L.
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20778
Subject(s) - hypophosphatemia , myeloid leukemia , imatinib mesylate , medicine , imatinib , oncology , chemotherapy , leukemia , gastroenterology , immunology
Imatinib is the drug of first choice for most patients with chronic phase chronic myeloid leukemia (CML). Although it is generally well tolerated, a number of hematological and nonhematological side‐effects have been described. We report here that imatinib induces hypophosphatemia in a high proportion of our series of CML patients previously treated with interferon α, and that this previously unreported side effect is associated with response. Am. J. Hematol., 2007. © 2006 Wiley‐Liss, Inc.